| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6159498 | ADALVO | Bioerodable film for delivery of pharmaceutical compounds of mucosal surfaces |
Oct, 2016
(7 years ago) | |
| US7579019 | ADALVO | Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces |
Jan, 2020
(4 years ago) | |
| US9579288 | ADALVO | Tesofensine and beta blocker combination formulations |
Jul, 2027
(3 years from now) | |
| US9597288 | ADALVO | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(3 years from now) | |
Onsolis is owned by Adalvo.
Onsolis contains Fentanyl Citrate.
Onsolis has a total of 4 drug patents out of which 2 drug patents have expired.
Expired drug patents of Onsolis are:
- US6159498
- US7579019
Onsolis was authorised for market use on 16 July, 2009.
Onsolis is available in film;buccal dosage forms.
Onsolis can be used as management of breakthrough pain in patients with cancer.
The generics of Onsolis are possible to be released after 23 July, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 16, 2012 |
Drugs and Companies using FENTANYL CITRATE ingredient
Market Authorisation Date: 16 July, 2009
Treatment: Management of breakthrough pain in patients with cancer
Dosage: FILM;BUCCAL
More Information on Dosage
ONSOLIS family patents
